Sugi Predict

Sugi Predict / Targets / DPY30

DPY30

Protein dpy-30 homolog (Dpy-30-like protein) · Q9C005 · DPY30 on Sugi Atlas →

1,661 patent compounds predicted against DPY30, 1,437 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL15004646 SCHEMBL15004646 0.79 5/20
SCHEMBL15004656 SCHEMBL15004656 0.79 5/20
SCHEMBL15004659 SCHEMBL15004659 0.79 5/20
SCHEMBL15005695 SCHEMBL15005695 0.79 5/20
SCHEMBL15005735 SCHEMBL15005735 0.79 5/20
SCHEMBL15004652 SCHEMBL15004652 0.78 5/20
SCHEMBL15005758 SCHEMBL15005758 0.78 5/20
SCHEMBL15004651 SCHEMBL15004651 0.77 5/20
SCHEMBL15005841 SCHEMBL15005841 0.74 5/20
SCHEMBL15004665 SCHEMBL15004665 0.74 5/20
SCHEMBL15004653 SCHEMBL15004653 0.73 5/20
SCHEMBL15005651 SCHEMBL15005651 0.69 5/20
SCHEMBL15028628 SCHEMBL15028628 0.69 5/20
SCHEMBL15004655 SCHEMBL15004655 0.65 5/20
SCHEMBL15004660 SCHEMBL15004660 0.65 5/20
SCHEMBL15004662 SCHEMBL15004662 0.65 5/20
SCHEMBL15004663 SCHEMBL15004663 0.65 5/20
SCHEMBL15004664 SCHEMBL15004664 0.65 5/20
SCHEMBL15005648 SCHEMBL15005648 0.65 5/20
SCHEMBL15005700 SCHEMBL15005700 0.65 5/20

Clinical trials — most relevant to DPY30 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment PHASE4RECRUITING
Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision PHASE3COMPLETED
Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer PHASE2UNKNOWN
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination PHASE1/PHASE2COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors PHASE1COMPLETED
Novel Peptide Vaccination for Patients With Advanced Bladder Cancer PHASE1COMPLETED
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer PHASE1COMPLETED
A Study of APX3330 in Patients With Advanced Solid Tumors PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Brain Involvement in Dystrophinopathies Part 1 nanCOMPLETED
Evaluation of Brain Dysfunction in Patients with Duchene Muscular Dystrophy nanNOT_YET_RECRUITING
Brain Involvement in Dystrophinopathies Part 2 nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Improving the Safety of Fluoropyrimidine-based Chemotherapy nanUNKNOWN
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines. nanCOMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins. nanUNKNOWN
Hereditary Nonpolyposis Colorectal Cancer in Taiwan-Related Genetic Study and Clinical Applications nanUNKNOWN
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
Exercise on Expression of Heat Shock Protein 70 in Arterial Risk nanCOMPLETED
Telomeres Length in Israeli Fibrotic ILD Patients nanENROLLING_BY_INVITATION
Consortium On Risk for Early-onset Parkinson's Disease (CORE PD) nanCOMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients nanCOMPLETED
Impact of Seasonal Malaria Chemoprevention on Immunity Against Malaria Among Children in Northern Benin nanCOMPLETED
Implementation of Molecular Diagnostic Pathways nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a DPY30 binder may also engage these)

ProteinNameSimilarity
Q99LT0 — 1.000 Q99LT0 →
Q2NKU6 — 1.000 Q2NKU6 →
Q8K3E7 — 0.998 Q8K3E7 →
O74861 — 0.992 O74861 →
Q290F0 — 0.985 Q290F0 →
Q10661 — 0.984 Q10661 →
Q3KNY5 — 0.984 Q3KNY5 →
Q5ICL9 — 0.984 Q5ICL9 →
O43150 — 0.984 O43150 →
Q03818 — 0.983 Q03818 →
G5EFD2 — 0.983 G5EFD2 →
Q6C5P0 — 0.983 Q6C5P0 →
Q00422 — 0.983 Q00422 →
G5EDY0 — 0.983 G5EDY0 →
C3KJF2 — 0.982 C3KJF2 →
O13786 — 0.982 O13786 →
Q9HDW4 — 0.982 Q9HDW4 →
Q08639 — 0.982 Q08639 →
Q9M358 — 0.982 Q9M358 →
Q60MF5 — 0.982 Q60MF5 →
Q03323 — 0.982 Q03323 →
P41412 — 0.982 P41412 →
P33411 — 0.982 P33411 →
A6ZML8 — 0.982 A6ZML8 →
Q86Y13 — 0.981 Q86Y13 →
A1ZB42 — 0.981 A1ZB42 →
Q5AAF4 — 0.981 Q5AAF4 →
Q756C4 — 0.981 Q756C4 →
Q06546 — 0.981 Q06546 →
O13870 — 0.981 O13870 →